ly 293111 has been researched along with Palmoplantaris Pustulosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Bakker, ES; De Jong, EM; Parker, GL; Seijger, MM; Van De Kerkhof, PC; Van Erp, PE; Van Hooijdonk, CA; Van Pelt, JP; Van Vlijmen, IM | 1 |
| Kooijmans-Otero, ME; Mommers, JM; Parker, GL; van de Kerkhof, PC; Van Rossum, MM | 1 |
2 trial(s) available for ly 293111 and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis.
Topics: Adult; Aged; Benzoates; Dermatologic Agents; Double-Blind Method; Female; Humans; Immunoenzyme Techniques; Macrophage-1 Antigen; Male; Middle Aged; Neutrophils; Prospective Studies; Psoriasis; Receptors, Leukotriene B4; Treatment Outcome; Up-Regulation | 1998 |
VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Benzoates; Clobetasol; Drug Therapy, Combination; Flow Cytometry; Glucocorticoids; Humans; Leukotriene Antagonists; Leukotriene B4; Psoriasis; Recurrence; Severity of Illness Index | 2000 |